Q-Line Biotech Limited

# SECTION VI- FINANCIAL INFORMATION OF THE COMPANY

## INDEPENDENT AUDITOR'S EXAMINATION REPORT ON RESTATED CONSOLIDATED FINANCIAL INFORMATION

To,
The Board of Directors of
Q-LINE BIOTECH LIMITED,

298-281, Transport Nagar,
Kanpur Road Adjacent Transport Nagar Metro Station,
Lucknow, Uttar Pradesh, India, 226012

Dear Sir,

1. We have examined the attached Restated Consolidated Financial Statement of Q-LINE BIOTECH LIMITED (hereunder referred to "the Company", "Issuer") comprising the Restated Consolidated Statement of Assets and Liabilities as at March 31, 2025, March 31, 2024, and March 31, 2023, the Restated Consolidated Statement of Profit & Loss, the Restated Consolidated Cash Flow Statement for the year ended March 31, 2025, March 31, 2024, and March 31, 2023, the statement of Significant Accounting Policies and other explanatory Information (Collectively the Restated Consolidated Financial Statement). These Restated Consolidated Financial Statement have been prepared by the Company and approved by the Board of Directors in their meeting held on 24th September, 2025 for the purpose of inclusion in the Draft Red Herring Prospectus/Red Herring Prospectus/ Prospectus ("Offer Document") in connection with its proposed Initial Public Offering (IPO) of equity shares in connection with its Initial Public Offer of Equity Shares (IPO).

2. These Restated Consolidated Financial Statements have been prepared in accordance with the requirements of:

a) Section 26 of Part I of Chapter III of the Companies Act, 2013 as amended ("the Act") read with Rules 4 to 6 of the Companies (Prospectus and Allotment of Securities) Rules, 2014 (the "Rules");

b) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 as amended ("ICDR Regulations");

c) The terms of reference to our engagement letter with the Company requesting us to carry out the assignment, in connection with the Draft offer document/ offer document being issued by the Company for its proposed Initial Public Offering of equity shares in SME Platform of NSE ("IPO" or "SME IPO"); and

d) The Guidance Note on Reports in Company Prospectuses (Revised 2019) issued by the Institute of Chartered Accountants of India as amended from time to time. ("The Guidance Note")

3. The Company's Board of Directors is responsible for the preparation of the Restated Consolidated Financial Statement for the inclusion in the offer document to be filed with Stock Exchange, Securities and Exchange Board of India, and Registrar of Companies of relevant state in connection with the proposed IPO. The Restated Consolidated Financial Statements have been prepared by the management of the Company for the year ended on March 31, 2025, March 31, 2024, and March 31, 2023 on the basis of Significant Accounting Policies and Notes to Accounts as set out in Annexure IV to the Restated Financial Statement. The Board of Directors responsibility includes designing, implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Consolidated Financial Information. The Board of Directors is also responsible for identifying and ensuring that the Company complies with the Companies Act, (ICDR) Regulations and the Guidance Note as issued by ICAI.

4. These Restated Consolidated Financial Information have been compiled by the management from Audited Consolidated Financial Statements of the Company for the year ended on 31st March 2025, 31st March 2024, and 31st March 2023 prepared in accordance with Accounting Standard as prescribed under section 133 of the Act and other accounting principles generally accepted in India. The Consolidated Financial Statement for the Year ended on March 31, 2024, and March 31, 2023 have been Audited by Mayank Mehrotra & Associates vide report dated 02nd September, 2024 and 02nd September, 2023, respectively and for the Year ended on March 31, 2025 have been audited by us vide our report dated 19th September, 2025.

5. We have examined such Restated Consolidated Financial Statement taking into consideration:

a) Terms of reference and terms of our engagement agreed upon with you in accordance with our engagement letter in connection with the proposed IPO of equity shares of the Company;

179